EMA — authorised 21 April 2017
- Application: EMEA/H/C/004179
- Marketing authorisation holder: Triskel EU Services Ltd
- Local brand name: Solithromycin Triskel EU Services
- Indication: Treatment of bacterial infections
- Status: withdrawn
🇪🇺 CEM-101 in European Union
EMA authorised CEM-101 on 21 April 2017
Marketing authorisation
Other Oncology approved in European Union
Frequently asked questions
Is CEM-101 approved in European Union?
Yes. EMA authorised it on 21 April 2017.
Who is the marketing authorisation holder for CEM-101 in European Union?
Triskel EU Services Ltd holds the EU marketing authorisation.